The Jenex Corp. plans to test TherOZap, its next-generation technology, against the Zika and West Nile viruses.

Jenex enlisted an independent lab and healthcare network to conduct the tests, which will determine whether the technology can be effective in deactivating the viruses. The company said it will provide an update on initial test results in the near future.

The U.S. FDA granted Jenex a class 2 medical device status for its platform technology, which is indicated for the relief of pain, itch and inflammation caused by insect stings and bites.